<DOC>
	<DOCNO>NCT00718250</DOCNO>
	<brief_summary>The purpose study assess safety tolerability 'AML Cell Vaccine ' patient poor prognosis acute myeloid leukaemia ( AML ) .</brief_summary>
	<brief_title>Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 ( CD80 ) IL-2</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis AML define accord WHO classification Age ≥ 18 year New presentation relapse AML Patients must able give write informed consent Failure enter complete morphological remission ( &gt; 5 % bone marrow AML cell ) persistence cytogenetic abnormality follow intensive combination chemotherapy At day+100 posttransplant HIV negative No GvHD No continue use immunosuppressive drug Absence active systemic fungal viral infection include HTLV1 , hepatitis B C. Adequate renal liver function confirm : creatinine clearance &gt; 30mls/min ; bilirubin &lt; 3.0 x upper limit normal ; AST &lt; 3.0 x upper limit normal ; prothrombin time &lt; 2.0 x upper limit normal . Performance status 1 less ECOG criterion &gt; 80 % Karnovsky score Patient must provide write informed consent willing comply duration study . Life expectancy &gt; 36 week Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 10 14 day within 24 hour start study . In addition , sexually active WCBP must agree continued abstinence heterosexual intercourse use adequate contraceptive method start 4 week prior initiation therapy ( see appendix G pregnancy test birth control guideline study ) . WCBP must agree pregnancy test every 3 week study drug ( every 14 day woman irregular cycle ) 4 week last dose study drug . Men must also agree use condom partner child bear potential , even successful vasectomy . Age &lt; 18 year Patients fit intensive chemotherapy Complete morphological cytogenetic remission follow intensive combination chemotherapy Absence HLA compatible donor HIV positive Evidence graft versus host disease day+100 post transplant Evidence relapse leukaemia ( ≥5 % bone marrow blast ) Concurrent use form antileukaemic therapy Other malignancy exception carcinoma situ . Significant history heart disease ( unstable angina , myocardial within past six month , congestive cardiac failure require daily treatment ) Evidence active lung disease determine chest xray absence chronic lung disease ( FEV1 &lt; 60 % predict , Vital capacity &lt; 60 % , Tlco &lt; 50 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Acute myeloid leukaemia</keyword>
	<keyword>Cancer vaccine</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>